Itravil 30 mg capsule (Clobenzorex)
Itravil 30 mg capsule (Clobenzorex) is a metabolic precursor of amphetamine indicated for the treatment of obesity. Amphetamines have been involved with cardiovascular side effects such as hypertension and pulmonary arterial hypertension.
Clobenzorex, N-(2-clorobenzyl)-amphetamine is an appetite suppressant indicated for the treatment of obesity, available in many countries (e.g., Mexico) as a prescription drug.
Clobenzorex (Asenlix, Dinintel, Finedal, Rexigen) is a stimulant drug of the phenethylamine and amphetamine chemical classes used as an appetite suppressant. The drug is legally distributed in Mexico under the trade name Asenlix by Aventis.
Introduction Itravil 30 mg capsule (Clobenzorex)
Chemically, clobenzorex is an N-substituted amphetamine analog that is converted to d-amphetamine soon after ingestion. In commercial production, clobenzorex is supplied in 30 mg doses as the hydrochloride salt in green-tinted capsules. The drug gained use as a prescription anorectic in the 1970s; however, adverse reactions were eventually observed, which led to the prohibition of clobenzorex in the United States and certain other countries.
Clobenzorex is a relatively new anorectic drug that has been cited in the literature the last couple of years.
It is not available in the United States, but is available in other countries such as Mexico, Spain, Argentina, and France.
Clobenzorex is manufactured by Hoechst Marion Roussel as a 30 mg capsule, dark/light green in color and marked with HMR. Clobenzorex metabolizes to d-amphetamine and has amphetamine-like central stimulant behavioral properties.
• Symptoms include dry mouth, significant excitation, increase alertness and difficulty sleeping.
• Approximately 20 times less potent than (+)amphetamine
• 20% of a dose can be accounted for (after 24 hrs) as d-amphetamine or amphetamine metabolite.
• Principal metabolites excreted in urine of rats: 40% glucuronide, 5% amphetamine, 3% phydroxyamphetamine.
• Clinical studies